title: Drugs take the spotlight in steering clinical, economic direction for ESRD.
authors.forename: Mark E
authors.initials: ME
authors.lastname: Neumann
mesh_terms: D003362:Cost-Benefit Analysis; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D017048:Health Care Costs; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000191:economics*; D006278:Medicare / Q000458:organization & administration*; D011050:Policy Making; D011787:Quality of Health Care; D014481:United States